JNJ-89402638 Phase 2 Study Initiated for Metastatic Colorectal and Gastric Cancers
A Phase 2 study is underway to assess the safety and optimal administration of JNJ-89402638 in mCRC and mGAC patients.
Company
Pharmaceutical intelligence for JNJ-89402638 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.